13.03.2014
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG appoints top US pharmaceuticals manager Bernhard Hampl to the Advisory Board
Formycon AG / Key word(s): Change of Personnel
13.03.2014 08:40
Dissemination of a Corporate News, transmitted by DGAP - a company of EQS
Group AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Munich - Formycon AG has expanded its Advisory Board. With Dr. Bernhard
Hampl, a top pharmaceuticals manager from the US has been acquired for the
advisory body.
Over the past 20 years, Dr. Bernhard Hampl was a successful CEO in large
American generics companies such as EON LABS Inc. and later Sandoz US,
which after fusion of the two companies became America's second-largest
manufacturer of generics. Dr. Hampl, who started his career at the German
subsidiary of American Cyanamid / Lederle in Wolfratshausen near Munich,
has been living in Connecticut/USA for the past 20 years and brings
wide-ranging international experience to Formycon. Today, he advises
companies from the field of pharmaceuticals and biotechnology as well as
investment companies. For Formycon AG, which has now progressed into the
advanced phases of preclinical development with its first projects and is
striving for international cooperations - above all in the USA - the
expertise provided by Dr. Hampl, who has a doctorate in the field of
pharmaceutical chemistry, represents a very valuable addition to the
competences of the Advisory Boards.
Dr. Carsten Brockmeyer, CEO of Formycon AG, said. "I'm very pleased that we
were able to enlist Dr. Bernhard Hampl, a recognised expert who knows his
way around the US pharmaceuticals market and who successfully built up and
managed several pharmaceutical companies in the USA. His competence will be
highly regarded in the Advisory Board."
About Formycon AG:
Formycon AG is a leading independent developer of biosimilars for global
marketing and has taken on a clear pioneering role in this field. The team
of the present Formycon AG has amassed many years of experience in the
development of complex molecules. As early as 2008 and 2011, two
protein-based product portfolios were licensed out to large pharmaceutical
companies. As a result of its particular expertise, Formycon AG is in a
position to develop high-quality biosimilars that fulfil the strict
requirements of the marketing authorisation authorities in the highly
regulated countries and regions such as Europe and the USA. Formycon
currently has two products under development, with the first biosimilar
candidate already having been licensed out to Santo Holding GmbH. Further
product developments are in the planning phase. The aim is to be the first
company in the world to present clinical data for each respective product
candidate and thus to license the products out to large pharmaceutical and
generics companies for further development. Alternatively, Formycon offers
to bring the biosimilars to marketing authorisation on behalf of the
licensee and take over production.
Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany
Tel. +49 (0) 89 - 86 46 67 100
Fax + 49 (0) 89 - 86 46 67 110
[email protected]
www.formycon.com
Disclaimer:
This press release may contain future-oriented statements and information
that are recognisable by formulations such as 'expect', 'want',
'anticipate', 'intend', 'plan', 'believe', 'strive', 'estimate', 'will be'
or similar terms. Such forward-looking statements are based on our
expectations today and on certain assumptions that may entail a range of
risks and uncertainties. The results actually achieved by Formycon AG may
deviate considerably from the declarations in the future-related
statements. Formycon AG will not undertake any commitment to update these
future-oriented statements or to correct them in the event that the
situation develops differently than expected.
13.03.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 145
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
E-mail:
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Freiverkehr in Berlin; Frankfurt in Open Market (Entry
Standard)
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB